Thermalin Inc.

[Available On-Demand]
Search General Info
Search Education
Search Partnering Companies
Thermalin hopes to disrupt the $30B insulin/insulin delivery market with a disposable, postage-stamp-sized glucose management system enabled by our first-in-class stabilized, highly concentrated and ultra-rapid acting insulin.

This wearable, connected, sensor-laden, combination device (a 36 x 33 x 6.5 mm, 8 g system that we call “StampPump”) could enable a new economic paradigm for diabetes management. Thermalin’s new insulin is the "secret sauce" that allows this device to be one quarter the size of any other system while managing blood glucose for a full week. Our new insulin molecule (not just a new formulation) will also make possible a transformational shift in the economics of the insulin market toward insulin pumps with factory-filled reservoirs and value-based pricing/reimbursement.
Company Type:
Company Website:
Company HQ State:
Company HQ Country:
United States
Year Founded:
Main Therapeutic Focus:
Lead Product in Development:
Stabilized ultra-rapid insulin & StampPump combination delivery device
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Chief Executive Officer
Thermalin Inc.